New drugs against high blood pressure
New drugs against high blood pressure
Madalas nagtatanong ang mga tao sa mga botika tungkol sa mga gamot laban sa presyon ng bagong henerasyon na walang side effects. Pero sa totoong buhay, hindi ito nangyayari. Lahat ng epektibong gamot ay may kanya-kanyang side effects. Kailangan mong maglaan ng maraming oras kasama ang iyong doktor para piliin ang tamang grupo ng gamot laban sa high blood pressure para sa'yo.
УЗНАТЬ ПОДРОБНЕЕ >>>
New drugs against high blood pressure: progress and prospects High blood pressure, known medically as hypertension, is a worldwide health problem and is considered to be one of the main risk factors for cardiovascular diseases such as heart attack, stroke, and kidney damage. According to estimates by the world health organization (WHO) affects about one billion people worldwide have hypertension. The development of new drugs for the effective reduction of blood pressure is therefore of high clinical and social relevance. Current Therapy Approaches Traditional treatment strategies include various drug classes: ACE inhibitors (eg, Enalapril), which inhibit the formation of Angiotensin II; AT1‑receptor blockers (e.g., Losartan), which prevent the action of Angiotensin II to its receptors; Beta-blockers (e.g., Metoprolol), the lower the heart rate and force; Calcium channel blockers (e.g. amlodipine), which relax the smooth muscles of the blood vessels; Diuretics (such as hydrochlorothiazide) to reduce the liquid content in the body. In spite of this wide range of options that are resistant hypertension) remains a part of the patient's blood pressure is adequately controlled (or unwanted side effects. This motivates the search for new drugs. Latest Developments In the last few years, several innovative approaches have been developed: Endothelin‑receptor antagonists (e.g., Bosentan): they inhibit the effect of the strong Vasoconstrictor Endothelin‑1 and the show, especially in the case of special forms of hypertension (for example, in the case of chronic renal insufficiency), with promising results. Renin inhibitors (such as Aliskiren): By direct inhibition of the enzyme Renin, the whole of the Renin‑Angiotensin‑aldosterone System is broken‑cascade at an early stage. Studies show an effective reduction in blood pressure, however, must be evaluated in long-term data on safety more. Vasopeptidase inhibitors: Combined inhibition of Neprilysin (an enzyme that natriure degrades tables peptides) and ACE. This dual effect leads to greater vasodilation and Natriuresis. Immune therapeutic approaches: Experimental studies of antibodies against Angiotensin II or its receptors to investigate. This could allow a long-lasting blood pressure control. Gene and RNA‑based therapies: approaches to targeted inhibition of the Expression of blood pressure‑regulating proteins (e.g. by means of siRNA against AGTR1) are in preclinical phases. Clinical trials and effectiveness Several Phase III trials confirm the efficacy of new substances: In patients with resistant hypertension, the Addition of a Renin‑Inhibitor resulted in a significant reduction in systolic blood pressure by an average of 15.2 mmHg in comparison to the placebo group (p<0,001). Endothelin‑antagonists reduced the mean pulmonary arterial pressure in patients with pulmonary hypertension significantly (to be -10.3 mmHg, 95% CI: -13.1 with to -7.5). Challenges and future prospects Although these new drugs are promising, there are challenges: possible side effects (e.g., Hyperkalemia in Renin inhibitors); high costs in comparison to established therapies; Need for long-term data for the reduction of cardiovascular endpoints. The future of hypertension therapy is located in the personalization: Genetic testing that might allow prediction of individual efficacy and tolerability say. In addition, innovative delivery systems (for example, implants for continuous drug release) to open up new opportunities to improve therapy adherence. Conclusion The development of new drugs against high blood pressure expands the therapeutic options, and it provides patients with resistant or difficult-to-use yet hypertension, a new hope. Interdisciplinary research and innovative technologies will continue to drive progress in this area.
Ektrak mula sa prutas ng cranberry Ektrak mula sa prutas ng appleberry Magnesium L-Arginin Ektrak mula sa dahon at bulaklak ng hawthorn Pulbos ng bulaklak ng hibiscus Ektrak mula sa dahon ng oliba Ektrak mula sa buto ng ubas Ektrak mula sa black currant Coenzyme Q10 Bitamina B6 Folate New drugs against high blood pressure. Isang malawak na pagpipilian ng mga gamot mismo pati na rin ng mga pamamaraan para sa pagbawas ng gamot mula sa mataas na presyon ang nagbibigay-daan sa iyo na pumili ng pinaka-komportableng programa ng paggamot – ang abot-kaya sa gastos, na may minimal na pagpapakita ng mga side effect, at isinasaalang-alang ang ibang kasamang sakit. Kapag matagal ang pag-inom ng tabletas at binabago ng doktor ang gamot, ito ay dahil ang ilang gamot ay may katangian na magdulot ng pagkagumon, na nagreresulta sa kaunting pagbaba ng bisa nito. Bukod dito, hindi lahat ng grupo ng gamot ay angkop para sa mga pasyente sa iba't ibang edad, at may mga limitasyon din sa pagiging compatible nito sa ibang uri ng gamot.
Arterial hypertension cardiovascular diseases
Complex medication for high blood pressure
Arrhythmia Cardiovascular Disease Causes
What type of heart disease you know
https://instant.wl9.ru/posts/16890-the-likelihood-of-cardiovascular-disease.html
https://lanoticia.hn/advert/stages-of-cardiovascular-diseases/
Diuretiko (Diuretika) ay nagpapataas ng pag-ihi ng katawan, na nagreresulta sa pagbaba ng presyon ng dugo. Simpleng paliwanag: Ang tuloy-tuloy na pag-ihi ng katawan ay nagdudulot ng pagbaba ng dami ng plasma sa dugo at sa gayon ay mas kaunting likido sa mga ugat — bumababa ang presyon sa mga pader ng ugat. Nililinis ang mga ugat na kailangang alagaan mula sa deposito at pinananatili ang kinakailangang lakas ng tibok ng puso!